Robert Montgomery, MD
Advanced Heart Failure and Transplant Cardiology · Cleveland, OHNPI 1023421062
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,435 of the $9,260 with a category attached, or 69.5%. Bayer accounts for 73.2% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $7,233, more than ten times the $71 reported in 2022.
Across 49 payments — averaging $188.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$7K
- Abbott$2K
- Abiomed$308
- E.r. Squibb & Sons, L.L.C.$102
- AstraZeneca$93
- Alnylam Pharmaceuticals Inc.$59
- plus $173 from 7 others
Across 2 payments — averaging $1624.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Consulting fees$6,43569%
- Travel & lodging$98711%
- Food & beverage$1,83720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 6 | $6,780 |
| Abbott | 16 | $1,744 |
| Abiomed | 6 | $308 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| AstraZeneca | 4 | $93 |
| Alnylam Pharmaceuticals Inc. | 2 | $59 |
| Lantheus Medical Imaging, Inc. | 2 | $50 |
| Boehringer Ingelheim | 2 | $31 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$6,564
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,541
- Impella$149
How this compares
$9,260 in reported general payments places this provider in the 65th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 43 | $1,154,131 |
| EntrestoSacubitril/Valsartan | 293 | $334,230 |
| JardianceEmpagliflozin | 276 | $302,565 |
| EliquisApixaban | 109 | $132,112 |
| FarxigaDapagliflozin Propanediol | 60 | $60,375 |
| XareltoRivaroxaban | 17 | $20,458 |
| Metoprolol Succinate | 245 | $2,713 |
| Isosorbide Dinitrate | 18 | $2,672 |
| Tacrolimus | 17 | $2,258 |
| Eplerenone | 23 | $1,866 |
| Torsemide | 77 | $1,862 |
| Colchicine | 11 | $1,621 |
| Spironolactone | 278 | $1,533 |
| Atorvastatin Calcium | 131 | $1,411 |
| Mycophenolate Mofetil | 12 | $900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $12 | $1,286,243152 claims |
| Boehringer IngelheimJardiance | $31 | $302,565276 claims |
| AstraZenecaFarxiga | $93 | $60,37560 claims |
| Johnson & JohnsonXarelto | $20 | $20,45817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cleveland
- Andres Carmona RubioCleveland$27K
- Pavan BhatCleveland$16K
- Sanjeeb BhattacharyaCleveland$7K
- Tuoyo Mene-AfejukuCleveland$6K
- Ran LeeCleveland$5K
- Chonyang AlbertCleveland$4K
- Amanda VestCleveland$4K
- Leon ZhouCleveland$3K
- Karlee HoffmanCleveland$2K
- Michael HillCleveland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.